LPR2 Ultra Low Pressure Reducing Regulator | Equilibar

LPR2 Ultra Low Pressure Reducing Regulator

Port Sizes:
1/4"
Max Pressure (Std Body Mat’l)
28 in WC
Body Material (Standard):
cast zinc body with aluminum cap;
Body Material (Optional):
some caps come with polyurethance O-ring
Key Applications:
  • Lowest pressure range available in its class
  • For low-flow or no-flow applications only
  • Extremely sensitive and stable
  • For air and inert gases
Product Description
LPR2 ultra low pressure reducing regulator

LPR2 Ultra Low Pressure Reducing Regulator

The Equilibar LPR2 is a manually adjustable pressure reducing regulator for inert gas or air in applications that are static or require ultra-low flow rates. The LPR2 accepts a 5-30 psig regulated gas supply and regulates the pressure to a reduced value based on the setting on the adjustable hand knob. The LPR2 is a non-relieving regulator. A small bleed to atmosphere orifice may be integrated for applications that do not consume downstream gas.

Videos
LPR2 ultra low pressure reducing regulator

LPR2 Ultra Low Pressure Reducing Regulator

High Precision Ultra Low Pressure Reducing Regulator – LPR2

Equilibar Low Pressure High Flow Regulator

Downloads
Applications
LPR2 ultra low pressure reducing regulator

LPR2 Ultra Low Pressure Reducing Regulator

Additional Specs
LPR2 ultra low pressure reducing regulator

LPR2 Ultra Low Pressure Reducing Regulator

Weight:

1.2 lbs (0.54 kg)

Dimensions:

 

 

 

Dimensions in inches
 

 

 

Fitting/Threads:

Standard: NPT

How It Works
LPR2 ultra low pressure reducing regulator

LPR2 Ultra Low Pressure Reducing Regulator

Related Products

Equilibar News
PUK magazine cover with stainless steel device

Journal article focuses on oligonucleotide production using pressure control with built in dampener

Oligonucleotide drugs are made up of short sections of genetic sequences and are used to target disorders in the genetic code. The first drug of this type was used in 1998 during the AIDS epidemic.  Since then, the field has accelerated rapidly and today many oligonucleotide drugs are in clinical trials, promising improvements in treatment Read More

Read More